NONMEM Population Pharmacokinetic Modeling of Orally Administered Cyclosporine From Routine Drug Monitoring Data After Heart Transplantation
- 1 June 1998
- journal article
- research article
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 20 (3) , 284-293
- https://doi.org/10.1097/00007691-199806000-00008
Abstract
The population pharmacokinetics of cyclosporine (CsA) in adult recipients of cardiac transplants were determined from sparse, retrospective drug monitoring data accumulated for at least 3 months after surgery. All were receiving oral CsA twice daily, and morning trough levels in whole-blood were measured by high-performance liquid chromatography. Additional data included height, weight, gender, age, ethnicity, hematocrit, total bilirubin, and concurrent drug use. Population modeling was performed using NONMEM on 36 randomly selected patients, assuming a one-compartment model with first-order absorption and elimination. Improved fits were obtained by incorporating the following expression in the model to adjust oral bio-availability as a function of postoperative day (POD): F = 0.2 + 10 × ABS (POD - 7) /([POD + 10] × 60). Interpatient variability (CV%) in clearance (CL) was 20.2%. There was a mean bias of 8.5% at the average CsA concentration of 250 ng/ml when the predictive performance was assessed statistically in a reserved subset of 33 patients who received cardiac transplants. For the entire population (n = 69 patients), the average CsA CL and terminal half-life (T1/2) were, respectively: CL (l/h) = 0.256× weight (kg); T1/2 = 11.0 hours, or CL (l/h) = 0.184× weight (kg); T1/2 = 14.7 hours, if there was concomitant diltiazem administration. These results compared favorably with those reported elsewhere for studies of postcardiac transplant kinetics using the traditional multiple blood sampling approach.Keywords
This publication has 32 references indexed in Scilit:
- Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantationClinical Pharmacology & Therapeutics, 1993
- Population Pharmacokinetics/Dynamics*Annual Review of Pharmacology and Toxicology, 1992
- A prospective study of cyclosporine concentration in relation to its therapeutic effect and toxicity after renal transplantation.British Journal of Clinical Pharmacology, 1990
- Cyclosporine Monitoring in Renal TransplantationTherapeutic Drug Monitoring, 1989
- Intraindividual variability in the relative systemic availability of cyclosporin after oral dosingEuropean Journal of Clinical Pharmacology, 1988
- DEMOGRAPHIC FACTORS AFFECTING THE PHARMACOKINETICS OF CYCLOSPORINE ESTIMATED BY RADIOIMMUNOASSAYTransplantation, 1986
- Population PharmacokineticsClinical Pharmacokinetics, 1986
- Clinical Pharmacokinetics of CyclosporinClinical Pharmacokinetics, 1986
- IMMUNOLOGICAL AND PHARMACOLOGICAL MONITORING IN THE CLINICAL USE OF CYCLOSPORIN AThe Lancet, 1981
- Estimation of population characteristics of pharmacokinetic parameters from routine clinical dataJournal of Pharmacokinetics and Biopharmaceutics, 1977